As per the research report, the size of the Asia Pacific Ophthalmic Drugs market size is valued at around USD 6.64 billion in 2020. It is expected to grow at a CAGR of 6.9% and worth USD 9.27 billion by 2025. It captures 20% of the global market share.
Ophthalmic drugs are used for the treatment of various eye disorders like cataracts, glaucoma, etc.
An increasing number of people suffering from glaucoma worldwide, high innovation in and heavy funding in the development of combination therapies are the major factors driving the growth of this market.
Adverse side-effects and long gestation periods in the development of new drugs hamper market growth.
This research report on the Asia Pacific market has been segmented and sub-segmented into the following categories:
By Therapeutic Class:
By Product Type:
By Distribution Channel:
By Disease Indications:
By Dosage Form:
By Technology:
By Country:
Geographically, Asia Pacific is the fastest growing market and will continue its growth streak till the end of 2025.
Promising companies operating in the Asia-Pacific Ophthalmic Drugs Market profiled in this report are Carl-Zeiss AG, Ellex Medical Lasers Ltd., Hoya Corporation, Novagali Pharma S A, Abbott Medical Optics, Inc., Essilor International S.A. Other players in the market include Insight Vision Inc., Nidek Co.Ltd, Topcon Corporation, and Ziemer Ophthalmic Systems AG.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Therapeutic Class
5.1.1 Introduction
5.1.2 Anti-inflammatory Drugs
5.1.2.1 Nonsteroidal Anti-inflammatory Drugs
5.1.2.2 Steroids
5.1.3 Anti-infective Drugs
5.1.3.1 Anti-fungal Drugs
5.1.3.2 Anti-bacterial Drugs
5.1.3.3 Others
5.1.4 Anti-glaucoma Drugs
5.1.4.1 Alpha Agonist
5.1.4.2 Beta Blockers
5.1.4.3 Prostaglandin Analogs
5.1.4.4 Combined Medication
5.1.4.5 Others
5.1.5 Anti-allergy Drugs
5.1.6 Anti-VEGF Agents
5.1.7 Others
5.1.8 Y-o-Y Growth Analysis, By Therapeutic Class
5.1.9 Market Attractiveness Analysis, By Therapeutic Class
5.1.10 Market Share Analysis, By Therapeutic Class
5.2 Product Type
5.2.1 Introduction
5.2.2 Prescription Drugs
5.2.3 Over-the-Counter Drugs
5.2.4 Y-o-Y Growth Analysis, By Product Type
5.2.5 Market Attractiveness Analysis, By Product Type
5.2.6 Market Share Analysis, By Product Type
5.3 Distribution Channel
5.3.1 Introduction
5.3.2 Hospital Pharmacies
5.3.3 Online Pharmacies
5.3.4 Independent Pharmacies & Drug Stores
5.3.5 Y-o-Y Growth Analysis, By Distribution Channel
5.3.6 Market Attractiveness Analysis, By Distribution Channel
5.3.7 Market Share Analysis, By Distribution Channel
5.4 Disease Indications
5.4.1 Introduction
5.4.2 Dry Eye
5.4.3 Glaucoma
5.4.4 Infection/Inflammation
5.4.5 Retinal Disorders
5.4.5.1 Wet Age-related Macular Degeneration
5.4.5.2 Dry Age-related Macular Degeneration
5.4.5.3 Diabetic Retinopathy
5.4.5.4 Others
5.4.6 Allergy
5.4.7 Uveitis
5.4.8 Others
5.4.9 Y-o-Y Growth Analysis, By Disease Indications
5.4.10 Market Attractiveness Analysis, By Disease Indications
5.4.11 Market Share Analysis, By Disease Indications
5.5 Dosage Form
5.5.1 Introduction
5.5.2 Liquid Ophthalmic Drug Forms
5.5.3 Solid Ophthalmic Drug Forms
5.5.4 Semisolid Ophthalmic Drug Forms
5.5.5 Multicompartment Drug Delivery Systems
5.5.6 Other Ophthalmic Drug Forms
5.5.7 Y-o-Y Growth Analysis, By Dosage Form
5.5.8 Market Attractiveness Analysis, By Dosage Form
5.5.9 Market Share Analysis, By Dosage Form
5.6 Technology
5.6.1 Introduction
5.6.2 Biologics
5.6.3 Cell Therapy
5.6.4 Gene Therapy
5.6.5 Drug Delivery
5.6.6 Small molecule
5.6.7 Others
5.6.8 Y-o-Y Growth Analysis, By Technology
5.6.9 Market Attractiveness Analysis, By Technology
5.6.10 Market Share Analysis, By Technology
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Therapeutic Class
6.1.3.3 By Product Type
6.1.3.4 By Distribution Channel
6.1.3.5 By Disease Indication
6.1.3.6 By Dosage Form
6.1.3.7 By Technology
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Therapeutic Class
6.1.4.3 By Product Type
6.1.4.4 By Distribution Channel
6.1.4.5 By Disease Indication
6.1.4.6 By Dosage Form
6.1.4.7 By Technology
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Therapeutic Class
6.1.5.3 By Product Type
6.1.5.4 By Distribution Channel
6.1.5.5 By Disease Indication
6.1.5.6 By Dosage Form
6.1.5.7 By Technology
6.2 China
6.3 India
6.4 Japan
6.5 South Korea
6.6 Australia
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Abbott Medical Optics, Inc.
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Carl-Zeiss AG
8.3 Ellex Medical Lasers Ltd.
8.4 Essilor International S.A.
8.5 Hoya Corporation
8.6 Insight Vision Inc.
8.7 Nidek Co.Ltd
8.8 Novagali Pharma S A
8.9 Topcon Corporation
8.10 Ziemer Ophthalmic Systems AG.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Feb 2020
